Why the epidermal growth factor receptor? The rationale for cancer therapy

Oncologist

Volumn 7, Issue SUPPL. 4, 2002, Pages 2-8

  Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

EGFR; EGFR TKIs; Monoclonal antibodies; ZD1839(Iressa )

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHOXY)PHENYL]CROTONAMIDE; 4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AS 21; CANERTINIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GW 57201; LAPATINIB; MATUZUMAB; MDX 447; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; THERACIM H R3; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR; QUINAZOLINE DERIVATIVE;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; HUMAN; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0036362181     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_4-2     Document Type: Review

References (66)

1. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents
2. The hallmarks of cancer
3. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
4. New technologies in epidermal growth factor receptor-targeted cancer therapy
5. Tyrosine kinase inhibitors: A clinical perspective
6. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
7. Single-molecule imaging of EGFR signalling on the surface of living cells
8. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
9. Specificity within the EGF family/ErbB receptor family signaling network
10. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
11. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
12. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers
13. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
14. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
15. Regulation of cell death protease caspase-9 by phosphorylation
16. Multiple positive and negative regulators of signaling by the EGF-receptor
17. The epidermal growth factor receptor (EGFR) - A new target in cancer therapy
18. The epidermal growth factor receptor and its inhibition in cancer therapy
19. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival
20. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells
21. Altered gene expression in drug-resistant human breast cancer cells
22. Epidermal growth factor-related peptides and their receptors in human malignancies
23. Epidermal growth factor receptor dependence in human tumors: More than just expression?
24. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
25. Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin
26. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors
27. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
28. The EGF receptor family as targets for cancer therapy
29. 1 arrest in prostatic cancer cell line DU145
30. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
31. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
32. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
33. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
34. Inhibition of p21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa')
35. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
36. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 ('Iressa'), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
37. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA an intermediate marker of EGFR activation, correlates with tumor growth inhibition
38. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
39. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
40. Epidermal growth factor receptor biology (IMC-C225)
41. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
42. Statistical growth curve modeling of tumors treated with ERBITUX™ (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation
43. ZD 1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer
44. Potentiation of cytotoxic drug activity in human cancer cells by ZD1839 ('Iressa') an EGFR-selective tyrosine kinase inhibitor
45. Cardiac dysfunction in the trastuzumab clinical trials experience
46. Anticancer therapy targeting the erbB family of receptor tyrosine kinases
47. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC)
48. Single agent IMC-225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
49. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
50. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen
51. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU), and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR)
52. Results of a phase I trial of the humanized antiepidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR-expressing solid tumors
53. ZD1839 (Iressa™) in non-small-cell lung cancer
54. ZD1839 (Iressa™): What's in it for the patient?
55. ZD1839 (Iressa™): For more than just non-small-cell lung cancer
56. Phase II study of ZD1839 ('Iressa') in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
57. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2)
58. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)
59. Preclinical evaluation of the combination of epidermal growth factor inhibitor ZD1839 (Iressa) and irinotecan (SN-38) in human colon cancer cells
60. A phase I study of ZD1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
61. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774 following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
62. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
63. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma
64. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel
65. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin
66. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (G) and cisplatin (P) in patients with advanced solid tumors